Alkol Biotech

alkolbiotech.co.uk

Alkol Biotech is a research company focused on the development of new plant varieties adapted to the needs of specific biofuel markets. The company adapts plant varities to grow in colder and dryer climates, offering better resistance to pests and diseases, and higher productivities. This allows the development of healthy biofuel markets in countries which otherwise have to import biomass in order to produce biofuels sustainably. Our first crop is a sugarcane hybrid focused on the european market for cellulosic ethanol production. It will offer up to 200 tons of biomass per hectare, 31% fiber, and will be the main source of biomass for Europe's 5% 2nd generation limit in the year 2020.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

EYEBIO RAISES $65M IN SERIES A FUNDING TO DEVELOP NEW GENERATION OF EYE DISEASE THERAPIES

Eyebiotech Limited | February 23, 2022

news image

Eyebiotech Limited a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the completion of a successful $65 million Series A funding round. SV Health Investors led the round, alongside Samsara BioCapital and Jeito Capital, with additional financial backing from MRL Ventures. The Series A brings together an international team of executives and investors with an extensive track record for developing ground-breaking o...

Read More

Medical

STRAMSEN BIOTECH, INC. TO FUND NEXT PHASES OF CLINICAL TRIALS AND ADDITIONAL MEDICINE DISCOVERY RESEARCH

Stramsen Biotech, Inc | December 17, 2020

news image

Stramsen Biotech, Inc, a professional group of medication researchers from the Houston, Texas territory comprises of scientists who devote their lives each day to investigating and exploring both the cycles and logical instruments hidden the world we live in today. Colleagues have gotten a few honors and awards for research ventures, with a significant number of their activities and distributions accessible upon demand. Individuals incorporate PhD and University level professors who specialize i...

Read More

Industrial Impact

OMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCESOMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCES

OMass Therapeutics | February 21, 2022

news image

OMass Therapeutics a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below. “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bou...

Read More

MedTech, Medical

BAYLOR COLLEGE OF MEDICINE HUMAN GENOME SEQUENCING CENTER ADOPTS OLINK® EXPLORE HT PROTEOMICS PLATFORM

Globenewswire | August 09, 2023

news image

Olink Holding AB announced that the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) has selected the Olink Explore platform as a proteomics component of their world-class multiomics offering. Understanding the complex biological mechanisms of human diseases is essential to identifying effective new therapeutic strategies. The addition of Olink proteomic technology enables a more thorough understanding of the intricate connections between genes, proteins, and...

Read More
news image

Industrial Impact

EYEBIO RAISES $65M IN SERIES A FUNDING TO DEVELOP NEW GENERATION OF EYE DISEASE THERAPIES

Eyebiotech Limited | February 23, 2022

Eyebiotech Limited a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the completion of a successful $65 million Series A funding round. SV Health Investors led the round, alongside Samsara BioCapital and Jeito Capital, with additional financial backing from MRL Ventures. The Series A brings together an international team of executives and investors with an extensive track record for developing ground-breaking o...

Read More
news image

Medical

STRAMSEN BIOTECH, INC. TO FUND NEXT PHASES OF CLINICAL TRIALS AND ADDITIONAL MEDICINE DISCOVERY RESEARCH

Stramsen Biotech, Inc | December 17, 2020

Stramsen Biotech, Inc, a professional group of medication researchers from the Houston, Texas territory comprises of scientists who devote their lives each day to investigating and exploring both the cycles and logical instruments hidden the world we live in today. Colleagues have gotten a few honors and awards for research ventures, with a significant number of their activities and distributions accessible upon demand. Individuals incorporate PhD and University level professors who specialize i...

Read More
news image

Industrial Impact

OMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCESOMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCES

OMass Therapeutics | February 21, 2022

OMass Therapeutics a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below. “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bou...

Read More
news image

MedTech, Medical

BAYLOR COLLEGE OF MEDICINE HUMAN GENOME SEQUENCING CENTER ADOPTS OLINK® EXPLORE HT PROTEOMICS PLATFORM

Globenewswire | August 09, 2023

Olink Holding AB announced that the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) has selected the Olink Explore platform as a proteomics component of their world-class multiomics offering. Understanding the complex biological mechanisms of human diseases is essential to identifying effective new therapeutic strategies. The addition of Olink proteomic technology enables a more thorough understanding of the intricate connections between genes, proteins, and...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us